TP53 / del(17p) — Targeted Therapies, Trials & Pipeline

TP53 aberration (mutation or del(17p)) is the dominant adverse predictive marker across many malignancies; in CLL it defines high-risk disease that should receive continuous targeted therapy rather than chemoimmunotherapy.